MENU
BMED
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BMED stock forecast, quote, news & analysis

The investment seeks to maximize total return... Show more

Category: #Health
BMED
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BMED with price predictions
Jul 02, 2026

BMED in +2.87% Uptrend, growing for three consecutive days on June 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BMED advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on BMED as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

BMED moved above its 50-day moving average on June 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BMED crossed bullishly above the 50-day moving average on June 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 251 cases where BMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

BMED broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Abbott Laboratories (NYSE:ABT), Gilead Sciences (NASDAQ:GILD), Intuitive Surgical (NASDAQ:ISRG), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Medtronic plc (NYSE:MDT), McKesson Corp (NYSE:MCK).

Industry description

The investment seeks to maximize total return. Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. While the fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants.

Market Cap

The average market capitalization across the iShares Health Innovation Active ETF ETF is 41.54B. The market cap for tickers in the group ranges from 69.27M to 633.19B. JNJ holds the highest valuation in this group at 633.19B. The lowest valued company is TCRX at 69.27M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Health Innovation Active ETF ETF was 5%. For the same ETF, the average monthly price growth was 13%, and the average quarterly price growth was 4%. MDT experienced the highest price growth at 19%, while ROG experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the iShares Health Innovation Active ETF ETF was 53%. For the same stocks of the ETF, the average monthly volume growth was 101% and the average quarterly volume growth was 177%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 66
Price Growth Rating: 44
SMR Rating: 79
Profit Risk Rating: 80
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
BMED
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
BlackRock ETF Trust100 BELLEVUE PARKWAY
Phone
N/A
Web
www.blackrock.com
BMED in +2.87% Uptrend, growing for three consecutive days on June 29, 2026